Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

Development and Evaluation of Sample treatment platform for infectious disease immunoassays

Reference number
Coordinator Biopromic AB
Funding from Vinnova SEK 1 450 005
Project duration January 2019 - December 2020
Status Completed

Purpose and goal

Many rapid tests lack sensitivity due to the presence of inhibitory molecules. We have developed a technology to easily get rid of the unwanted components and thereby significantly increase the sensitivity. We have proven it in a test for tuberculosis. We wanted to test the same technology for other infectious diseases such as pneumonia and legionella.

Expected results and effects

Unfortunately, it turned out that the technology could not contribute to any improvement of the two diseases named above.

Planned approach and implementation

Sample collected from patients at hospital and commercially available tests in the market obtained, and our technology implemented aiming to increase the test sensitivity. The results scored either by naked eyes or a reader.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 28 January 2021

Reference number 2018-03896

Page statistics